These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Recombinant soluble transforming growth factor beta type II receptor ameliorates radiation enteropathy in mice. Zheng H; Wang J; Koteliansky VE; Gotwals PJ; Hauer-Jensen M Gastroenterology; 2000 Nov; 119(5):1286-96. PubMed ID: 11054386 [TBL] [Abstract][Full Text] [Related]
9. A transforming growth factor-beta antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury. Ruocco A; Nicole O; Docagne F; Ali C; Chazalviel L; Komesli S; Yablonsky F; Roussel S; MacKenzie ET; Vivien D; Buisson A J Cereb Blood Flow Metab; 1999 Dec; 19(12):1345-53. PubMed ID: 10598939 [TBL] [Abstract][Full Text] [Related]
10. Soluble transforming growth factor-beta type II receptor inhibits negative remodeling, fibroblast transdifferentiation, and intimal lesion formation but not endothelial growth. Smith JD; Bryant SR; Couper LL; Vary CP; Gotwals PJ; Koteliansky VE; Lindner V Circ Res; 1999 May; 84(10):1212-22. PubMed ID: 10347096 [TBL] [Abstract][Full Text] [Related]
11. Distinct patterns of transforming growth factor-beta isoform and receptor expression in human atherosclerotic lesions. Colocalization implicates TGF-beta in fibrofatty lesion development. Bobik A; Agrotis A; Kanellakis P; Dilley R; Krushinsky A; Smirnov V; Tararak E; Condron M; Kostolias G Circulation; 1999 Jun; 99(22):2883-91. PubMed ID: 10359732 [TBL] [Abstract][Full Text] [Related]
12. Suppression of cyclosporine a nephrotoxicity in vivo by transforming growth factor beta receptor-immunoglobulin G chimeric protein. Xin J; Homma T; Matsusaka T; Ma J; Isaka Y; Imai E; Ichikawa I Transplantation; 2004 May; 77(9):1433-42. PubMed ID: 15167603 [TBL] [Abstract][Full Text] [Related]
13. Transglutaminase 2 deficiency decreases plaque fibrosis and increases plaque inflammation in apolipoprotein-E-deficient mice. Van Herck JL; Schrijvers DM; De Meyer GR; Martinet W; Van Hove CE; Bult H; Vrints CJ; Herman AG J Vasc Res; 2010; 47(3):231-40. PubMed ID: 19893320 [TBL] [Abstract][Full Text] [Related]
14. The expression of TGF-beta receptors in human atherosclerosis: evidence for acquired resistance to apoptosis due to receptor imbalance. McCaffrey TA; Du B; Fu C; Bray PJ; Sanborn TA; Deutsch E; Tarazona N; Shaknovitch A; Newman G; Patterson C; Bush HL J Mol Cell Cardiol; 1999 Sep; 31(9):1627-42. PubMed ID: 10471347 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Brånén L; Hovgaard L; Nitulescu M; Bengtsson E; Nilsson J; Jovinge S Arterioscler Thromb Vasc Biol; 2004 Nov; 24(11):2137-42. PubMed ID: 15345516 [TBL] [Abstract][Full Text] [Related]
16. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Van Aarsen LA; Leone DR; Ho S; Dolinski BM; McCoon PE; LePage DJ; Kelly R; Heaney G; Rayhorn P; Reid C; Simon KJ; Horan GS; Tao N; Gardner HA; Skelly MM; Gown AM; Thomas GJ; Weinreb PH; Fawell SE; Violette SM Cancer Res; 2008 Jan; 68(2):561-70. PubMed ID: 18199553 [TBL] [Abstract][Full Text] [Related]
17. Specific abrogation of transforming growth factor-beta signaling in T cells alters atherosclerotic lesion size and composition in mice. Gojova A; Brun V; Esposito B; Cottrez F; Gourdy P; Ardouin P; Tedgui A; Mallat Z; Groux H Blood; 2003 Dec; 102(12):4052-8. PubMed ID: 12920022 [TBL] [Abstract][Full Text] [Related]